Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered to “Buy” at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Monday.

Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Up 1.7 %

Shares of SUPN traded up $0.55 during trading hours on Monday, reaching $32.70. 380,535 shares of the company traded hands, compared to its average volume of 467,460. The stock has a market capitalization of $1.83 billion, a PE ratio of 30.56 and a beta of 0.83. The stock has a fifty day simple moving average of $35.58 and a 200 day simple moving average of $35.06. Supernus Pharmaceuticals has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by company insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of institutional investors have recently modified their holdings of SUPN. Natixis Advisors LLC lifted its position in Supernus Pharmaceuticals by 14.9% during the third quarter. Natixis Advisors LLC now owns 39,318 shares of the specialty pharmaceutical company’s stock valued at $1,226,000 after buying an additional 5,113 shares in the last quarter. Quest Partners LLC acquired a new position in shares of Supernus Pharmaceuticals during the 3rd quarter valued at $241,000. Segall Bryant & Hamill LLC purchased a new stake in Supernus Pharmaceuticals during the 3rd quarter worth $791,000. Intech Investment Management LLC increased its holdings in Supernus Pharmaceuticals by 16.2% in the 3rd quarter. Intech Investment Management LLC now owns 13,161 shares of the specialty pharmaceutical company’s stock valued at $410,000 after purchasing an additional 1,838 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Supernus Pharmaceuticals by 14.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after purchasing an additional 91,354 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.